• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Discovery of human Glutaminyl Cyclase inhibitors for the treatment of Alzheimer's disease

Research Project

Project/Area Number 16F16385
Research Category

Grant-in-Aid for JSPS Fellows

Allocation TypeSingle-year Grants
Section外国
Research Field Chemical biology
Research InstitutionInstitute of Physical and Chemical Research

Principal Investigator

ZHANG KAM  国立研究開発法人理化学研究所, 生命機能科学研究センター, チームリーダー (60558906)

Co-Investigator(Kenkyū-buntansha) VIJAYAN DILEEP  国立研究開発法人理化学研究所, 生命機能科学研究センター, 外国人特別研究員
Project Period (FY) 2016-11-07 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 2018: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2017: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2016: ¥700,000 (Direct Cost: ¥700,000)
KeywordsAlzheimer's disease / Glutaminyl cyclase / Drug design / Virtual screening
Outline of Annual Research Achievements

Human glutaminyl cyclase (hQC) is an important enzyme which mediates the formation of pGlu-Aβ peptides and hence it has been considered as a potential target for the drug discovery against Alzheimer’s disease (AD). In our studies an effort has been taken to identify potential inhibitors against hQC. Two potential inhibitors of hQC have been identified with nano-molar inhibition capacity. Structure based design has been carried out and 16 analogues of these compounds were synthesized. Their enzymatic assay has been carried out against hQC. The studies suggested that all of the analogues exhibited quite promising activities (all in nano molar inhibition) except two molecules. Their co-crystal structures were determined and structure activity relationship has been studied. The blood brain barrier permeability of these compounds has also been carried out. A few of the compounds exhibited promising BBB penetrability. The dissociation constants and cytotoxicity profiling of these compounds are currently being carried out. The IC50 values of two H3R antagonists such as clobenpropit and thioperamide have been determined. These compounds exhibited moderate activities against hQC. Furthermore, the co-crystal structures of these compounds with hQC were also determined at atomic resolution. The studies will be beneficial for the designing of multi-target directed ligands.

Research Progress Status

平成30年度が最終年度であるため、記入しない。

Strategy for Future Research Activity

平成30年度が最終年度であるため、記入しない。

Report

(3 results)
  • 2018 Annual Research Report
  • 2017 Annual Research Report
  • 2016 Annual Research Report
  • Research Products

    (2 results)

All 2017

All Presentation (2 results)

  • [Presentation] Structure based design of peptide inhibitors against human glutaminyl cyclase2017

    • Author(s)
      Dileep K. V. and Kam Y. J. Zhang
    • Organizer
      The 7th Biennale RIKEN Joint Retreat
    • Place of Presentation
      Hamamatsu, Shizuoka, Japan
    • Year and Date
      2017-02-02
    • Related Report
      2016 Annual Research Report
  • [Presentation] Structure based design of peptide inhibitors against human glutaminyl cyclase2017

    • Author(s)
      Dileep K. V. and Kam Y. J. Zhang
    • Organizer
      Takeda Symposium on Bioscience. Chronic Inflammation - Initiation, Progression and Resolution
    • Place of Presentation
      Osaka, Japan
    • Year and Date
      2017-01-20
    • Related Report
      2016 Annual Research Report

URL: 

Published: 2016-11-08   Modified: 2024-03-26  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi